Comparative analysis of three genetic constructs for delivery and expression of a modified single-domain antibody gene in rAAV

Le résumé fourni par la source

Objectives. To obtain and compare the efficiency of three recombinant adeno-associated virus (rAAV) variants expressing the gene of the modified single-domain antibody B11-Fc specific to botulinum toxin type A (BoNT/A): rAAV-DJ-CMV-B11-Fc, rAAV-DJ-CASI-B11-Fc, and scAAV-DJ-CMV-B11-Fc. Methods. The AAV-DJ Packaging System ( Cell Biolabs , USA) was used to create target constructs and obtain rAAV. Expression of the B11-Fc antibody gene in the obtained rAAV was assessed in vitro (HEK293, CHO-S, and C2C12 cell lines) and in vivo (BALB/c mice) using biolayer interferometry. The protective properties of the drugs were investigated on the model of lethal intoxication of mice with BoNT/A. Results. The rAAV-DJ-CMV-B11-Fc drug demonstrated a high level of B11-Fc antibody production both in vitro and in vivo without a significant decrease in concentration for at least 6 months. Comparable levels of B11-Fc production were demonstrated by rAAV-DJ-CASI-B11-Fc and scAAV-DJ-CMV-B11-Fc drugs in both in vitro and in vivo studies, with the exception of C2C12 cells, where rAAV-DJ-CASI-B11-Fc demonstrated the highest efficacy. When investigating the protective activity of the drugs against a lethal dose of BoNT/A, it was found that rAAV-DJ-CASI-B11-Fc possessed more pronounced activity in the first two days following administration as compared to rAAV-DJ-CMV-B11-Fc. However, at later stages, starting from 3 months, the rAAV-DJ-CMV-B11-Fc drug product demonstrated the most pronounced protection against high doses of BoNT/A. Conclusions. The obtained data show that rAAV-DJ-CASI-B11-Fc should be used for the induction of protection against BoNT/A at early stages (24–48 h) after administration, whereas for protection against the highest doses of BoNT/A in the long term, rAAV-DJ-CMV-B11-Fc should be used. Studies into the specific activity of the drugs at later stages after administration are still ongoing.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.